LISATA THERAPEUTICS, INC. — Director's Dealing 2012

Jun 27, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2012-06-25

Reporting Person: SCHMIEG MARTIN E (Vice President- Corporate Dev)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.4	2022-05-28	Common Stock, par value $0.001 pershare (50000)		Direct

Footnotes

F1: On May 29, 2012 (the "Effective Date"), the Issuer and the Reporting Person entered into a consulting agreement, pursuant to which the Issuer granted the Reporting Person an option, subject to the terms andconditions of the Issuer's 2009 Equity Comepnsation Plan, to purchase 50,000 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), vesting as to: (i) 25,000 shares on theEffective Date and (ii) 25,000 shares on June 30, 2012. On June 25, 2012, the Compensation Committee of the Issuer's Board of Directors approved the acceleration of the vesting of such option such that itbecame fully vested on June 25, 2012, the date on which the Reporting Person entered into an employment agreement with the Issuer to serve as the Issuer's Vice President of Corporate Development.